查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
社区型细菌性肺炎市场－全球、区域和国家层面的分析与预测（2025-2035 年）
市场调查报告书
商品编码
1906304

社区型细菌性肺炎市场－全球、区域和国家层面的分析与预测（2025-2035 年）

Community-Acquired Bacterial Pneumonia Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 90 Pages | 商品交期: 1-5个工作天内

价格

社区型细菌性肺炎（CABP）是由在医疗机构外获得的细菌引起的肺部感染疾病。

这是最常见的肺炎类型，通常由细菌经由呼吸系统进入肺部引起，导致肺组织发炎和感染。社区型细菌性肺炎最常见的致病菌包括肺炎链球菌、流感嗜血桿菌和卡他莫拉菌，但其他细菌也可能引起此病。

社区型细菌性肺炎的常见症状包括发烧、咳嗽、胸痛、呼吸困难和疲倦。感染的严重程度从轻微到严重不等，可能需要住院治疗，尤其是在老年人、慢性病患者和免疫系统较弱等易感人群中。早期诊断和适当的抗生素治疗对于预防呼吸衰竭和败血症等併发症至关重要。预防措施包括接种疫苗、维持良好的卫生习惯和戒烟。透过适当的医疗管理，社区型细菌性肺炎的预后通常良好，但重症患者和合併基础疾病的患者可能需要更长的康復时间。

社区型肺炎，尤其是细菌性肺炎，是全球主要的致病和致死原因之一。光是在美国，每年就有约500万至600万人患有此病，成人住院率高达20%至30%。根据全球疾病负担研究，肺炎每年在全球造成超过1亿例，其中细菌病原体，特别是肺炎链球菌，最常见。如此高且不断增长的发病率是推动市场发展的主要动力，也促使人们需要更有效的诊断方法、治疗方案和预防策略。

全球医疗基础设施的大量投资在推动社区获得性细菌性肺炎市场成长方面发挥关键作用。各国政府和相关人员不断扩大医院设施、提升重症监护能力并改善诊断技术。例如，经合组织成员国预计2022年的平均医疗支出将占GDP的约9.7%，反映出各国持续重视强化医疗健康体系。印度等新兴经济体预计到2023年公共卫生支出将占GDP的2.1%，其中相当一部分将用于感染疾病防治和紧急应变。这些基础设施投资确保了快速诊断、先进的患者管理以及抗生素和疫苗的广泛应用。这一趋势不仅改善了患者的治疗效果，也推动了对相关治疗、诊断和支持性护理解决方案的需求，从而扩大了整体市场。

儘管取得了这些进展，社区型细菌性肺炎市场仍面临许多挑战。高成本是阻碍因素。开发新型抗生素和治疗方法需要大量的资金投入，包括研发、临床试验和监管核准。抗生素，尤其是针对抗药性菌株的抗生素，需要先进的研发技术和专门的生产流程。与生产、品管和分销相关的成本进一步加重了这一经济负担。这些因素往往限制了市场进入，尤其对于低收入社区和医保覆盖不足的患者而言更是如此。此外，製药公司还面临着如何在盈利需求和新药上市的高昂成本之间取得平衡的挑战，这可能导致创新治疗方法的上市延迟和供应有限，最终阻碍社区获得性细菌性肺炎市场的成长。

社区型细菌性肺炎（CABP）市场细分：

细分 1：按区域

  • 北美洲
  • 欧洲
  • 亚太地区

全球社区型细菌性肺炎市场正经历重大变革，新的机会正在重塑治疗模式并推动市场成长。该市场药物核准和上市数量的不断增加，为市场成长带来了巨大潜力。美国食品药物管理局(FDA) 和欧洲药品管理局 (EMA) 等监管机构正在加速核准创新抗生素和治疗方法，特别是针对多重抗药性细菌的疗法。随着全球抗生素抗药性的持续加剧，对新型高效治疗方法的需求日益增长。新药的核准为製药公司提供了契机，使其能够透过推出更有效、更具针对性的治疗方法来满足社区型细菌性肺炎领域尚未满足的医疗需求。

本报告考察了全球社区获得性细菌性肺炎市场，并总结了关键趋势、市场影响因素分析、法律制度、市场规模趋势和预测、按各个细分市场、地区/主要国家进行的详细分析、竞争格局以及主要企业的概况。

目录

执行摘要

第一章 全球社区型细菌性肺炎市场：产业分析

  • 市场概览与生态系统
  • 流行病学分析
  • 主要市场趋势
    • 影响分析
  • 监管状态
  • 管道分析
  • 市场动态
    • 概述
    • 市场驱动因素
    • 市场限制
    • 市场机会

2. 全球社区型细菌性肺炎市场（按地区划分）

  • 北美洲
  • 欧洲
  • 亚太地区
    • 市场动态
    • 市场规模及预测
    • 按国家/地区分類的市场规模和预测

第三章：竞争格局与公司概况

  • 竞争格局
    • M&A
    • 伙伴关係、联盟和业务拓展
    • 新服务
    • 监理活动
    • 资金筹措活动
  • 公司简介
    • Nabriva Therapeutics.
    • Paratek Pharmaceuticals
    • Eagle Pharmaceutical.
    • Merck & Co.
    • Pfizer Inc.
    • Takeda Pharmaceutical Company Limited. (TiGenix)
    • Melinta Therapeutics LLC.
    • Allergan Plc.
    • Theravance Biopharma Inc.
    • Pfizer, Inc.
    • 其他的

第四章调查方法

Product Code: BHL3533SA

Global Community-Acquired Bacterial Pneumonia Market, Analysis and Forecast: 2025-2035

Community-acquired bacterial pneumonia (CABP) is an infection of the lungs caused by bacteria that is contracted outside of a healthcare setting. It is one of the most common types of pneumonia and typically occurs when bacteria enter the lungs through the respiratory tract, leading to inflammation and infection in the lung tissue. The most common pathogens responsible for community-acquired bacterial pneumonia include Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis, though other bacteria can also cause the disease.

Symptoms of community-acquired bacterial pneumonia often include fever, cough, chest pain, difficulty breathing, and fatigue. The infection can range from mild to severe and may require hospitalization, particularly in vulnerable populations such as the elderly, those with chronic conditions, or individuals with compromised immune systems. Early diagnosis and treatment with appropriate antibiotics are crucial to prevent complications such as respiratory failure or sepsis. Prevention strategies include vaccination, good hygiene practices, and smoking cessation. With proper medical management, the prognosis for community-acquired bacterial pneumonia is generally favourable, although recovery may be prolonged in severe cases or for those with underlying health conditions.

Community-acquired pneumonia (CAP), particularly bacterial, is one of the leading causes of morbidity and mortality worldwide. In the U.S. alone, community-acquired pneumonia affects an estimated 5 to 6 million people each year, with hospitalization rates reaching 20-30% among adults. The Global Burden of Disease Study also highlights that pneumonia results in more than 100 million cases globally each year, with bacterial pathogens, particularly Streptococcus pneumoniae, being the most prevalent. This high and growing prevalence acts as a primary driver for the market, necessitating more effective diagnostics, treatment options, and preventive strategies.

Significant investments in healthcare infrastructure worldwide are playing a crucial role in driving the community-acquired bacterial pneumonia market. Governments and private sector stakeholders are continuously enhancing hospital facilities, expanding intensive care capabilities, and improving diagnostic technologies. For instance, OECD countries reported an average healthcare spending of around 9.7% of GDP in 2022, reflecting a sustained focus on strengthening health systems. In emerging economies such as India, public health expenditure rose to 2.1% of GDP in 2023, with major portions allocated to infectious disease control and emergency preparedness. Such infrastructural investments ensure timely diagnosis, advanced patient management, and broader accessibility to antibiotics and vaccines. This trend not only improves patient outcomes but also fuels demand for related therapeutics, diagnostics, and supportive care solutions, thereby expanding the overall market.

Despite these advances, the community-acquired bacterial pneumonia market faces several challenges. The high cost associated with the distribution and development of drugs is a significant constraint within the community-acquired bacterial pneumonia market. The process of developing new antibiotics and therapies requires substantial financial investment in research and development (R&D), clinical trials, and regulatory approvals. This is particularly true for antibiotics targeting resistant bacterial strains, which necessitate advanced research techniques and specialized production processes. The costs associated with manufacturing, quality control, and distribution further exacerbate the financial burden. These factors often result in limited market access, particularly in low-income regions or for patients with inadequate insurance coverage. Additionally, pharmaceutical companies face the challenge of balancing the need for profitability with the substantial costs of bringing a new drug to market, which can result in delays and reduced availability of innovative treatments, ultimately inhibiting the growth of the community-acquired bacterial pneumonia market.

The global community-acquired bacterial pneumonia market is highly competitive, with several leading companies driving innovation and growth, such as Nabriva Therapeutics, Paratek Pharmaceuticals, Eagle Pharmaceutical, Pfizer, Inc., and Merck & Co. Companies in the community-acquired bacterial pneumonia (CABP) market are adopting key strategies to boost growth. One approach is focusing on developing innovative drugs, especially targeting antibiotic-resistant bacteria, to meet unmet medical needs. Firms are also investing heavily in research and development to create more effective and broad-spectrum antibiotics and to improve drug delivery systems. To expand their market presence, companies are forming strategic partnerships and collaborations with research institutions, biotechnology firms, and other pharmaceutical firms to leverage expertise and accelerate product development.

Community-Acquired Bacterial Pneumonia Market Segmentation:

Segmentation 1: by Region

  • North America
  • Europe
  • Asia-Pacific

The global community-acquired bacterial pneumonia market is undergoing significant transformation, fuelled by emerging opportunities that are reshaping treatment paradigms and driving community-acquired bacterial pneumonia market growth. The growing number of drug approvals and launches in the community-acquired bacterial pneumonia market presents a promising opportunity for growth. Regulatory agencies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have been fast-tracking approvals for innovative antibiotics and therapies, especially those that target multidrug-resistant bacteria. As antibiotic resistance continues to rise globally, there is an increasing need for new, more effective treatments. The approval of new drugs provides pharmaceutical companies with the opportunity to capitalize on unmet medical needs by introducing more effective and targeted therapies for community-acquired bacterial pneumonia.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Community-Acquired Bacterial Pneumonia Market: Industry Analysis

  • 1.1 Market Overview and Ecosystem
  • 1.2 Epidemiological Analysis
  • 1.3 Key Market Trends
    • 1.3.1 Impact Analysis
  • 1.4 Regulatory Landscape
  • 1.5 Pipeline Analysis
  • 1.6 Market Dynamics
    • 1.6.1 Overview
    • 1.6.2 Market Drivers
    • 1.6.3 Market Restraints
    • 1.6.4 Market Opportunities

2. Global Community-Acquired Bacterial Pneumonia Market (by Region), Value ($Million), 2024-2035

  • 2.1 North America
    • 2.1.1 Market Dynamics
    • 2.1.2 Market Sizing and Forecast
    • 2.1.3 North America Community-Acquired Bacterial Pneumonia Market, by Country ($Million), 2024-2035
      • 2.1.3.1 U.S.
  • 2.2 Europe
    • 2.2.1 Market Dynamics
    • 2.2.2 Market Sizing and Forecast
    • 2.2.3 Europe Community-Acquired Bacterial Pneumonia Market, by Country ($Million), 2024-2035
      • 2.2.3.1 U.K.
      • 2.2.3.2 France
      • 2.2.3.3 Germany
      • 2.2.3.4 Italy
      • 2.2.3.5 Spain
  • 2.3 Asia-Pacific
    • 2.3.1 Market Dynamics
    • 2.3.2 Market Sizing and Forecast
    • 2.3.3 Asia-Pacific Community-Acquired Bacterial Pneumonia Market, by Country ($Million), 2024-2035
      • 2.3.3.1 Japan

3. Competitive Landscape and Company Profiles

  • 3.1 Competitive Landscape
    • 3.1.1 Mergers and Acquisitions
    • 3.1.2 Partnership, Alliances and Business Expansion
    • 3.1.3 New Offerings
    • 3.1.4 Regulatory Activities
    • 3.1.5 Funding Activities
  • 3.2 Company Profiles
    • 3.2.1 Nabriva Therapeutics.
      • 3.2.1.1 Overview
      • 3.2.1.2 Top Products / Product Portfolio
      • 3.2.1.3 Top Competitors
      • 3.2.1.4 Target Customers/End-Users
      • 3.2.1.5 Key Personnel
      • 3.2.1.6 Analyst View
    • 3.2.2 Paratek Pharmaceuticals
      • 3.2.2.1 Overview
      • 3.2.2.2 Top Products / Product Portfolio
      • 3.2.2.3 Top Competitors
      • 3.2.2.4 Target Customers/End-Users
      • 3.2.2.5 Key Personnel
      • 3.2.2.6 Analyst View
    • 3.2.3 Eagle Pharmaceutical.
      • 3.2.3.1 Overview
      • 3.2.3.2 Top Products / Product Portfolio
      • 3.2.3.3 Top Competitors
      • 3.2.3.4 Target Customers/End-Users
      • 3.2.3.5 Key Personnel
      • 3.2.3.6 Analyst View
    • 3.2.4 Merck & Co.
      • 3.2.4.1 Overview
      • 3.2.4.2 Top Products / Product Portfolio
      • 3.2.4.3 Top Competitors
      • 3.2.4.4 Target Customers/End-Users
      • 3.2.4.5 Key Personnel
      • 3.2.4.6 Analyst View
    • 3.2.5 Pfizer Inc.
      • 3.2.5.1 Overview
      • 3.2.5.2 Top Products / Product Portfolio
      • 3.2.5.3 Top Competitors
      • 3.2.5.4 Target Customers/End-Users
      • 3.2.5.5 Key Personnel
      • 3.2.5.6 Analyst View
    • 3.2.6 Takeda Pharmaceutical Company Limited. (TiGenix)
      • 3.2.6.1 Overview
      • 3.2.6.2 Top Products / Product Portfolio
      • 3.2.6.3 Top Competitors
      • 3.2.6.4 Target Customers/End-Users
      • 3.2.6.5 Key Personnel
      • 3.2.6.6 Analyst View
    • 3.2.7 Melinta Therapeutics LLC.
      • 3.2.7.1 Overview
      • 3.2.7.2 Top Products / Product Portfolio
      • 3.2.7.3 Top Competitors
      • 3.2.7.4 Target Customers/End-Users
      • 3.2.7.5 Key Personnel
      • 3.2.7.6 Analyst View
    • 3.2.8 Allergan Plc.
      • 3.2.8.1 Overview
      • 3.2.8.2 Top Products / Product Portfolio
      • 3.2.8.3 Top Competitors
      • 3.2.8.4 Target Customers/End-Users
      • 3.2.8.5 Key Personnel
      • 3.2.8.6 Analyst View
    • 3.2.9 Theravance Biopharma Inc.
      • 3.2.9.1 Overview
      • 3.2.9.2 Top Products / Product Portfolio
      • 3.2.9.3 Top Competitors
      • 3.2.9.4 Target Customers/End-Users
      • 3.2.9.5 Key Personnel
      • 3.2.9.6 Analyst View
    • 3.2.10 Pfizer, Inc.
      • 3.2.10.1 Overview
      • 3.2.10.2 Top Products / Product Portfolio
      • 3.2.10.3 Top Competitors
      • 3.2.10.4 Target Customers/End-Users
      • 3.2.10.5 Key Personnel
      • 3.2.10.6 Analyst View
    • 3.2.11 Others

4. Research Methodology

List of Figures

  • Figure: Community-Acquired Bacterial Pneumonia Market (by Scenario), $Million, 2024, 2030, and 2035
  • Figure: Global Community-Acquired Bacterial Pneumonia Market, 2024 and 2035
  • Figure: Global Community-Acquired Bacterial Pneumonia Market Key Trends, Impact Analysis
  • Figure: North America Community-Acquired Bacterial Pneumonia Market, $Million, 2024-2035
  • Figure: Europe Community-Acquired Bacterial Pneumonia Market, $Million, 2024-2035
  • Figure: Asia-Pacific Community-Acquired Bacterial Pneumonia Market, $Million, 2024-2035

List of Tables

  • Table: Market Snapshot
  • Table: Market Dynamics
  • Table: Global Community-Acquired Bacterial Pneumonia Market (by Region), $Million, 2024-2035